Combination therapy for the pharmacological management of benign prostatic hyperplasia: Rationale and treatment options

Drugs and Aging

Volumn 22, Issue 11, 2005, Pages 901-912

  Sandhu, Jaspreet S ^a   Darracott Vaughan Jr , E ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DOMAZOLINE; DUTASTERIDE; FINASTERIDE; HORMONE; PLACEBO; ROFECOXIB; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ASTHENIA; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; COLON POLYP; DISEASE COURSE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RELEASE; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEMATURIA; HORMONE SUBSTITUTION; HUMAN; HYPOTENSION; IMPOTENCE; INCIDENCE; LIBIDO DISORDER; LONG TERM CARE; MALE; MENOPAUSAL SYNDROME; NOSE CONGESTION; ORGAN SIZE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATECTOMY; RETROGRADE EJACULATION; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; THROMBOEMBOLISM; URINARY TRACT DISEASE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; CHOLESTENONE 5 ALPHA-REDUCTASE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; MALE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS;

EID: 28544441671     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200522110-00002     Document Type: Review

References (63)

1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
2. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED, et al., editors. Campbell's Urology. Philadelphia (PA): Saunders, 2002: 1297-1336
3. McConnell MD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63
4. McConnell JD, Roehrborn CG, Bautista AM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2385-96
5. McConnell JD. Prostatic growth: new insights into hormonal regulation. Br J Urol 1995; 76 Suppl. 1: 5-10
6. Imperato-McGinley J, Guerrero L, Gautieer T, et al. Steroid 5-alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213-5
7. Walsh PC, Madden JD, Harrod MJ, et al. Familial incomplete male pseudohermaphroditism type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291: 944-9
8. Shapiro E, Hartano V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immuno-enzymatic staining and color assisted image analysis. J Urol 1992; 147: 1167
9. Schwinn DA. Androgen receptors: unique localization in human tissues. Adv Pharmacol 1994; 31: 333-41
10. Lepor H, Gup DI, Baumann M, et al. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 1998; 32: 21-6
11. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guidelines. No. 8. AHCPR Publication: No. 94-0582. Rockville (MD): Agency for Health Care Policy and Research. Public Health Service, US Department of Health and Human Services, 1994
12. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-9
13. Girman CJ, Panser LA, Chute CG, et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol 1993; 150: 887-92
14. Blute MI, Jacobsen SJ, Kaplan SA, et al. Evaluation and management of benign prostatic hyperplasia: proceedings of a thought leader conference held March 31, 2001. Urology 2001; 58: 1-4
15. Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7
16. Rhodes T, Girman CJ, Jacobsen SJ, et al. Longitudinal prostate growth rates during 5 years in randomly selected men 40-79 years old. J Urol 1999; 161: 1174-9
17. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology 1999; 54: 662-9
18. Hoffman RM, MacDonald R, Slaton JW, et al. Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. J Urol 2003; 169: 210-5
19. Te AE, Malloy TR, Stein BS, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 2004; 172: 1404-8
20. Reich O, Bachmann A, Siebels M, et al. High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol 2005; 173: 158-60
21. Sandhu JS, Ng C, Vanderbrink BA, et al. High-power potassium-titanyl- phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology 2004; 64: 1155-9
22. Tunuguntla HS, Evans CP. Minimally invasive therapies for benign prostatic hyperplasia. World J Urol 2002; 20: 197-206
23. Gup DI, Shapiro E, Bauman M, et al. Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 1989; 15: 105-14
24. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
25. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9
26. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild-to-moderate essential hypertension: a double-blind, placebo controlled, dose-response multicenter study. J Urol 1995; 154: 110-5
27. AUA Practice Guideline Committee. AUA guidelines on management of benign prostatic hyperplasia (2003): diagnosis and treatment recommendations. Chapter 1. J Urol 2003; 170: 530-47
28. Walmsley K, Cjertsen CK, Kaplan SA. Medical management of BPH: an update. Campbell's Urology Updates 2004; 2 (2): 1-8
29. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia: Tamsulosin Investigator Group. Urology 1998; 51: 892-900
30. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003; 170: 498-502
31. Martin DJ. Preclinical pharmacology of a1-adrenoreceptor antagonists. Eur Urol 1999; 36 Suppl. 1: 35-41
32. van Kerrebroeck P, Jardin A, Laval KU, et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000; 37: 306-13
33. Lukacs B, Grange JC, Comet D, et al. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol 2000; 37: 183-90
34. Roehrborn CG, the ALFUS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953-9
35. Li X, Chen C, Singh SM, et al. The enzyme and inhibitors of 4-ene-oxosteroid 5 alpha-oxidoreductase. Steroids 1995; 60: 430-41
36. Rasmusson GH, Reynolds GF, Steinberg NG, et al. Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding. J Med Chem 1986; 29: 2298-315
37. Gromley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia: the Finasteride Study Group. N Engl J Med 1992; 327: 1185-91
38. Beisland HO, Binkowitz B, Brekkan E, et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992; 22: 271-7
39. Vaughan D, Imperato-McGinley J, McConnell J, et al. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002; 60: 1040-4
40. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999; 54: 670-8
41. Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001; 57: 1073-7
42. Matsumoto AM, Tenover L, McClung M, et al. The long term effect of specific type II 5-alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 2002; 167: 2105-8
43. Schafer W, Tammela TLJ, Barrett DM, et al. Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Urology 1999; 54: 278-83
44. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
45. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24
46. Bostwick DG, Qian J, Civantos F, et al. Does finasteride alter pathology of the prostate and cancer grading? Clin Prostate Cancer 2004; 2: 228-35
47. Scardino PT. The prevention of prostate cancer: the dilemma continues. N Engl J Med 2003; 349: 297-9
48. Vaughan ED. Medical management of benign prostatic hyperplasia: are two drugs better than one? N Engl J Med 2003; 349: 2449-51
49. Kearney MC, Bingham JB, Bergland R, et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002; 167: 2489-91
50. Pareek G, Shevchuk M, Armenakas NA, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003; 169: 20-3
51. Hagerty JA, Ginsberg PC, Harmon JD, et al. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000; 55: 684-9
52. Donahue JF, Sharma H, Abraham R. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002; 168: 2024-6
53. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533-9
54. Debruyne FE, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride, and the combination of both in the treatment of benign prostatic hyperplasia: European ALFIN Study Group. Eur Urol 1998; 34: 169-75
55. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-26
56. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostate Symptoms (MTOPS) trial. Control Clin Trials 2003; 24: 224-43
57. Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 2003; 61: 791-6
58. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003; 61: 354-8
59. Baldwin KC, Ginsberg PC, Roehrborn CG, et al. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58: 203-8
60. Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-6
61. Rossouw JE, Anderson GL, Prentice RI, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized control trial. JAMA 2002; 288: 321-33
62. FDA News. FDA issue public health advisory on Vioxx as its manufacturer voluntarily withdraws the product: FDA P04-95, September 30, 2004 [online]. Available from URL: http:// www.fda.gov/bbs/topics/news/2004/NEW01122.html [Accessed 2005 Sep 30]
63. Bambardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8